Zila Professional Pharmaceuticals introduces the ViziLite chemiluminescent test kit for use in conjunction with a conventional visual oral mucosal examination to improve the identification, evaluation and monitoring of oral mucosal abnormalities in those at increased risk for oral cancer.
The ViziLite device produces a diffuse light for approximately 10 minutes. The specific ViziLite wavelengths are absorbed by normal cells and reflected by abnormal cells (due to their higher nucleus-to-cytoplasm ratio). Lesions identified with the ViziLite product can be monitored, biopsied, treated, or excised, according to the clinician's judgment.
Prior to examination with the ViziLite device, the patient rinses with a 1% acetic solution, which is included in the test kit; this disrupts the glycoprotein barrier of mucosal surfaces, improving visualization of abnormal tissue.
For more information, contact Zila Professional Pharmaceuticals at (800) 922-7887.
